UBS Group
YCBD.PRA

UBS Group’s cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock YCBD.PRA Stock Holding History

UBS Group’s Portfolio YCBD.PRA Stock Details YCBD.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-580
Closed -$348 – 10581
2024
Q3 		$348 Buy
+580
New +$307 ﹤0.01% 8988
2024
Q2 		– Sell
-3,000
Closed -$2.48K – 10260
2024
Q1 		$2.48K Buy
3,000
+2,799
+1,393% +$1.87K ﹤0.01% 7892
2023
Q4 		$141 Buy
+201
New +$191 ﹤0.01% 8878
2023
Q3 		– Sell
-32
Closed -$101 – 10085
2023
Q2 		$101 Sell
32
-312
-91% -$980 ﹤0.01% 8510
2023
Q1 		$1.15K Buy
+344
New +$1.37K ﹤0.01% 8797
2022
Q4 		– Sell
-8,947
Closed -$31K – 11247
2022
Q3 		$31K Buy
+8,947
New +$31.9K ﹤0.01% 6846
2022
Q2 		– Sell
-1,313
Closed -$7K – 11083
2022
Q1 		$7K Sell
1,313
-259
-16% -$1.38K ﹤0.01% 8858
2021
Q4 		$9K Buy
+1,572
New +$9.62K ﹤0.01% 8941
2020
Q2 		– Sell
-3,683
Closed -$20K – 8444
2020
Q1 		$20K Sell
3,683
-475
-11% -$3.12K ﹤0.01% 6504
2019
Q4 		$34K Buy
+4,158
New +$37.4K ﹤0.01% 6577

Other funds holding YCBD.PRA

MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's YCBD.PRA Position: Q4 2024 in Review

UBS Group sold out of cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock (YCBD.PRA) in Q4 2024, closing a stake of 580 shares — an estimated $348 sold.

UBS Group first reported a position in YCBD.PRA in Q4 2019 and held it in 10 quarters. The position peaked at $34K in Q4 2019. 7 funds tracked by Wall St. Rank hold YCBD.PRA as of Q4 2024.

  • UBS Group reported no remaining cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock position as of Q4 2024 after selling out during the quarter.
  • UBS Group sold 580 cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock shares in Q4 2024, an estimated $348.
  • UBS Group first reported a position in cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock in Q4 2019 and held it in 10 quarters.
  • UBS Group's cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock position peaked at $34K in Q4 2019.
  • 7 funds tracked by Wall St. Rank held cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.